08.27.08
Chiltern has fully integrated its two early Phase units into a single operation branded as Chiltern Early Phase. This follows the acquisition of Drug Development Solutions (DDS) in February.
Chiltern Early Phase provides early phase services for the pharmaceutical industry through its two units in Slough (just outside of London) and Dundee, Scotland. Chiltern Early Phase has a total of 72 beds, 42 of which are based at Ninewells Hospital in Dundee and can cover all therapeutic areas and all types of clinical pharmacology studies, with specialization in first in man, drug photosensitivity, drug-drug interaction, Japanese bridging and vaccine studies.
Glenn Kerkhof, Chiltern's chief executive officer, said, "When we created Chiltern Early Phase, our vision was to develop a brand that would be synonymous with quality and service excellence. We now have the team, organization and facilities to deliver on this vision and provide a truly expert Early Phase service at reasonable cost."
Dr. Brian Sanderson, medical director of Chiltern Early Phase commented, "I am delighted to see the integration completed so thoroughly and ahead of schedule. We are now looking to build on our units' long histories of good science and medicine, both in the areas where we have traditionally been strong but also in new areas of specialization such as diabetes and cardiovascular medicine. We are also looking forward to forging academic links to provide specialist studies involving new biomarkers."
Chiltern Early Phase provides early phase services for the pharmaceutical industry through its two units in Slough (just outside of London) and Dundee, Scotland. Chiltern Early Phase has a total of 72 beds, 42 of which are based at Ninewells Hospital in Dundee and can cover all therapeutic areas and all types of clinical pharmacology studies, with specialization in first in man, drug photosensitivity, drug-drug interaction, Japanese bridging and vaccine studies.
Glenn Kerkhof, Chiltern's chief executive officer, said, "When we created Chiltern Early Phase, our vision was to develop a brand that would be synonymous with quality and service excellence. We now have the team, organization and facilities to deliver on this vision and provide a truly expert Early Phase service at reasonable cost."
Dr. Brian Sanderson, medical director of Chiltern Early Phase commented, "I am delighted to see the integration completed so thoroughly and ahead of schedule. We are now looking to build on our units' long histories of good science and medicine, both in the areas where we have traditionally been strong but also in new areas of specialization such as diabetes and cardiovascular medicine. We are also looking forward to forging academic links to provide specialist studies involving new biomarkers."